The Hyaluronidase Market was valued at USD 963.40 million in 2023 and is projected to reach USD 2032.10 million by 2032, growing at a CAGR of 8.69%. The U.S. market alone is expected to double, reaching USD 577.75 million by 2032, driven by FDA approvals and increased demand for oncology and aesthetic procedures.

Major players in the Hyaluronidase Market include Halozyme Therapeutics, AbbVie Inc., and Roche Holding AG. The market is segmented by type, application, formulation, and end-use, with animal-derived hyaluronidase dominating the market in 2023.

North America held the largest market share in 2023 at 40.62%, while Asia Pacific is expected to witness the highest CAGR of 9.42% from 2024-2032. Recent developments include FDA approvals for Tecentriq Hybreza and SKINVIVE by JUVÉDERM, driving innovation in the market.

S&S Insider offers unique sections in their report, including usage & prescription trends, healthcare & aesthetic spending metrics, regulatory approval & market penetration index, R&D investment & pipeline landscape, and regional demand differentiation. They aim to provide clients with accurate market data and insights to make informed decisions.

Read more at GlobeNewswire: Hyaluronidase Market Set to Reach USD 2.03 Billion by 2032,